-
Rukayya Sunusi Alkassim
VN-Biostat Fellow (2023–2024)PhD student, Statistics, Ahmadu Bello University (Nigeria)
-
Leila Azinfar
Postdoctoral Research FellowAsiaee LabPhD, Bioengineering, University of Missouri-Columbia
Research focus: applying statistical and machine learning methods to large-scale datasets of biological information; identifying causal relationships between regulatory molecules and specific biological processes to develop more targeted and effective treatments for a wide range of diseases and conditions
-
Chia-Jung "Charlene" Chang
Visiting Research ScholarPhD candidate, Biomedical Engineering, National Cheng Kung University (Taiwan)
Research interests include: single-cell RNA sequence analysis, high-dimensional data analysis, precision medicine, multi-omit meta-analysis, mathematical models, statistical and bioinformatics methodology, engineering mathematics, cancer biology
For more information: github.com/Charlene717
-
Jia Li
Postdoctoral FellowPhD, Bioinformatics, CAS-MPG Partner Institute for Computational Biology, Shanghai Technology University
Jia Li's work at Vanderbilt has included "Tuft cell heterogeneity in function, lineage, and structure in ideal inflammatory disease," "Combinatorial single-cell strategies for a Crohn's disease gut cell atlas," and "Mechanistic insights into histone deacetylase inhibition for the treatment of retinoblastoma."
Publications include "scMRMA: Single cell multiresolution marker-based annotation" (Nucleic Acids Research 2022)
Winner of the Best Poster award in the department's 20th anniversary poster session for "Single-cell and spatial transcriptomics clustering with an optimized adaptive k-nearest neighbor graph"
-
PhD student, Statistics, Ahmadu Bello University
-
Austin Shih
Research Intern (2023-2024)Senior, Applied Mathematics (Data Science and Economics minors), Vanderbilt University
Mentors: Yu Shyr and Chih-Yuan Hsu
Shih is focusing on the use of computer simulations to create new methods to determine sample size for running a randomized Phase III trial for treatment crossover with respect for all three kinds of endpoints (continuous, categorical, and survival).